The MYG1 Knockout KYSE-30 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the MYG1 gene is disrupted in the human KYSE-30 esophageal squamous cell carcinoma line. This loss-of-function model is generated using CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of cells with targeted ablation of MYG1 expression, suitable for functional studies without the confounding effects of clonal selection. The polyclonal format offers a versatile tool for investigating gene function in a population context.
The host KYSE-30 cell line is an adherent, well-differentiated human esophageal squamous cell carcinoma model that retains epithelial barrier properties and reflects the biology of stratified squamous epithelium. This cell line is widely employed in esophageal cancer research, providing a physiologically relevant background for exploring mitochondrial function and cancer metabolism.
MYG1 encodes a mitochondrial protein that functions as a co-chaperone in the assembly of oxidative phosphorylation (OXPHOS) complex I. It facilitates the insertion of iron-sulfur clusters and stabilizes intermediate subcomplexes, interacting with assembly factors such as NDUFAF1, TIMMDC1, ACAD9, ECSIT, and TMEM126B. The expression and activity of MYG1 are regulated by upstream factors including NRF1, PGC-1??, and HIF1A, placing it at the intersection of metabolic and hypoxic signaling. Downstream, MYG1 governs mitochondrial membrane potential, ATP synthesis, and reactive oxygen species (ROS) production. Consequently, disruption of MYG1 impairs electron transport and energy metabolism.
In the context of esophageal squamous cell carcinoma, MYG1 knockout enables dissection of mitochondrial contributions to tumor cell bioenergetics and survival. This model is particularly valuable for studying metabolic reprogramming and the adaptive response to hypoxia, processes frequently dysregulated in cancer. Because the knockout is delivered in a polyclonal format, it more closely mimics the heterogeneous gene inactivation observed in tumor cell populations, enhancing translational relevance.
The MYG1 Knockout KYSE-30 Polyclonal Cells are suited for a range of research applications, including mitochondrial disease modeling, cancer bioenergetics, and investigation of drug resistance mechanisms. Representative experimental assays include Seahorse metabolic flux analysis to measure oxygen consumption rate and extracellular acidification rate, complex I enzyme activity assays, ATP quantification, MitoSOX-based ROS detection, western blotting, and RT-qPCR. Researchers can utilize this model to probe interactions with pathway components like NDUFV1, NDUFS1, NDUFA9, and SDHA. For additional details, please contact Ascent Research.
